admin – Page 4382 – Get News Story

BountyBay Labs Unveils TradeOS: The Future of Decentralized Transactions with zk-TLS

BountyBay Labs, backed by leading investors TON Ventures and Animoca Brands, announces the launch of TradeOS — a modular, decentralized infrastructure to revolutionize online peer-to-peer (P2P) transactions. By harnessing advanced blockchain and zk-TLS/TEE-TLS technologies, TradeOS eliminates the long-standing issues of high platform fees, low fund efficiency, and data monopolies in traditional monopoly systems, such as eBay and Paypal.

With over 6 million users and 300+ brands already onboard, the TradeOS ecosystem is soaring up in the digital trading space. Its goal is simple yet ambitious: to revolutionise the $4 trillion global P2P transaction market by providing an open, efficient, and scalable blockchain-based trading system for users and businesses alike.

1 (1)

A New Standard: Permissionless, Trust-free Trading with ‘Proof-of-Delivery’

TradeOS makes P2P transactions safer and more efficient with its automated escrow system. Funds are securely held in smart contracts and only released once the Service Provider submits the ‘Proof-of-Delivery.’

This blockchain system eliminates the need for intermediaries: ‘Code-is-law’ — building the trust between parties in a tamper-proof and verifiable way. The ‘Proof-of-delivery’ system not only supports blockchain data, but also leveraging technologies like ZK-TLS and Oracle to interoperate with reliable Web2 data signals — truly break the data silo between Web2 and Web3 world, and operates in a privacy preserving way.

Why ZK-TLS & TEE-TLS Matters

ZK-TLS & TEE-TLS allows TradeOS to securely verify data from Web2 platforms without needing API integrations or centralized permissions. They generate verifiable zk-proofs that can be directly verified by smart contracts. Imagine proving your actions on platforms like Twitter or eBay without revealing sensitive details like your username or passing transaction history.

Target Markets: Unlocking $4 Trillion in Opportunities

TradeOS redefines P2P transaction systems across key high-value markets:

Online Product & Service Trading: escrow the trading for digital products, services, and real-world assets.
Cross-Border B2B Commerce: Stablecoins is a growing popular settlement tool to overcome currency conversion inefficiencies. TradeOS is the blockchain-native escrow system for seamless and low-cost international transactions.
Influencer Marketing: allow influencer auto-management via ‘Proof-of-Delivery’, support instant payout upon verification, and brand rug-pulls prevention.
Freelancer Market: Release funds only when services are successfully delivered.
Token OTC Trading: Facilitate over-the-counter crypto trades, crypto to FIAT swaps
And more…

TradeOS is unlocking a massive $4 trillion P2P transaction market while enabling secure and efficient operations for all participants.

2 (1)

Looking Ahead: AI, Meme, and More

TradeOS will soon launch an Omni-chain Meme Trading DEX and an AI auto-trading agent to the Bounty Bay app — with TradeOS protocol as the underlying cross-chain bridgeless infra.

Bounty Bay app is TradeOS’s self-managed marketplace in Telegram. It is designed for P2P online services trading in Telegram, serving 6M traders already and used to partner with many leading Web3 projects, such as OKX, Bybit, HashKey Global, Aethir, UXLink, Carv, Sending Network, QuestN, and GAMEE.

The Revolution for Online Trading

TradeOS is more than just infrastructure; it is the engine driving the next generation of decentralized payment systems. It’s the game-changing solution that unlocks massive potential for Web3 adoption.

Learn more about TradeOS and stay turned for AI Meme trading: X/Twitter: @TradeOS_ai | Website | Litepaper | Telegram News

To view original press release, please visit: https://prbuzz.co/news/1429722/bountybay-labs-unveils-tradeos-the-future-of-decentralized-transactions-with-zktls

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: TradeOS
Email: Send Email
Country: United States
Website: https://www.tradeos.xyz/

Trusted Oregon and Washington Appraisal Company Swift Valuation LLC Launches All-New Website

Clients across the region can now visit the all-new Swift Valuation LLC website to discover the full range of services available and book their free estimates

JANUARY 16, 2025 – The team at trusted appraisal company Swift Valuation LLC is excited to announce the official launch of its all-new website, which offers a seamless online hub where existing and prospective clients in Oregon and Washington State can learn more about the professional appraisals provided by this leading company.

Swift Valuation LLC opened its doors with a mission of providing appraisal services that clients in Oregon and Washington State could trust. Thus far, the company has proven itself with a successful track record of highly satisfied clients across the region. The team at Swift Valuation LLC is passionate about creating and providing credible appraisal reports, precise valuations, and simple processes that leave clients feeling confident about the service they’ve received. “My goal is to make obtaining an accurate valuation of your property an easy, pain-free experience. Let me make the appraisal the least stressful thing on your list,” said the team at Swift Valuation LLC.

Now, Swift Valuation LLC is forwarding its stance as a leader in local appraisals with the launch of an immersive new website where current and curious clients can learn more and book a free estimate. The website demonstrates Swift Valuation LLC’s commitment to its clients with a streamlined, all-in-one hub that offers an in-depth look at its real estate services, which extend to various real estate types including single family homes, duplexes, condos, land, and manufactured homes. Swift Valuation LLC appraises an average of $200 million in real estate each year and knows no bounds when it comes to accurate appraisals, seamlessly navigating even the most complex valuations. As a member of RMLS, NWMLS, and WVMLS, Swift Valuation LLC extends the height of client care and support to its clients at every step of the way.

At the newly launched Swift Valuation LLC website, anyone interested in an Oregon or Washington real estate appraisal can get a full list of the company’s coverage area to answer whether or not they are within the service area. If they are not, they can connect with the team at Swift Valuation LLC by inquiring via the contact section of the new website.

“We offer quality appraisal services with a personal touch,” said a spokesperson for the company. “We encourage anyone in the area to visit our new website now to learn more about the real estate appraisal services that people are talking about.”

Learn more now by visiting www.swift-valuation.com.

ABOUT SWIFT VALUATION LLC

Swift Valuation LLC offers certified residential real estate appraisals in Oregon and Washington State punctuated by the height of professionalism and expertise.

Media Contact
Company Name: Swift Valuation
Contact Person: Ryan Hughes
Email: Send Email
Phone: 503-705-8239
Country: United States
Website: https://www.swift-valuation.com/

Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Giant-Cell Arteritis pipeline constitutes 6+ key companies continuously working towards developing 6+ Giant-Cell Arteritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Giant-Cell Arteritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Giant-Cell Arteritis Market.

The Giant-Cell Arteritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Giant-Cell Arteritis Pipeline Report:

Companies across the globe are diligently working toward developing novel Giant-Cell Arteritis treatment therapies with a considerable amount of success over the years.
Giant-Cell Arteritis companies working in the treatment market are AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others, are developing therapies for the Giant-Cell Arteritis treatment

Emerging Giant-Cell Arteritis therapies in the different phases of clinical trials are- Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others are expected to have a significant impact on the Giant-Cell Arteritis market in the coming years.
In June 2024, Johnson & Johnson has decided to discontinue a mid-stage trial evaluating its monoclonal antibody Tremfya (guselkumab) for the treatment of giant cell arteritis after it failed to meet the primary endpoint. As per a clinical update on clinicaltrials.gov, the Phase II THEIA study did not achieve the primary goal—the percentage of participants attaining glucocorticoid (GC)-free remission. Specific details regarding the results were not provided. However, the company reported “insufficient efficacy findings,” which led to the decision to halt further support for the study, according to a J&J spokesperson’s email to BioSpace. The spokesperson also mentioned that no new safety issues were identified.
In April 2024, AbbVie has announced favorable initial results from the first phase of the Phase III SELECT-GCA trial assessing upadacitinib (RINVOQ; 15mg, once daily) in combination with a tapered steroid regimen for adults diagnosed with giant cell arteritis (GCA).

Giant-Cell Arteritis Overview

Giant-Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory condition that affects the blood vessels, particularly the large and medium-sized arteries in the head, including the temporal arteries. It primarily affects older adults, typically over the age of 50. The inflammation can lead to symptoms such as severe headaches, scalp tenderness, vision problems, and jaw pain while chewing. If left untreated, GCA can lead to serious complications, including permanent vision loss. The condition is typically treated with corticosteroids to reduce inflammation and prevent complications.

Get a Free Sample PDF Report to know more about Giant-Cell Arteritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight

Emerging Giant-Cell Arteritis Drugs Under Different Phases of Clinical Development Include:

Rinvoq(upadacitinib): AbbVie
Cosentyx (secukinumab): Novartis
KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals
Tremfya(guselkumab): Johnson & Johnson/ MorphoSys AG
Baricitinib: Eli Lilly and Company
Tocilizumab + Glucocorticoids (GCs): Roche Pharma
Secukinumab: Novartis
Guselkumab: Janssen Research & Development
Tocilizumab: Hoffmann-La Roche
adalimumab: Abbott
Upadacitinib: AbbVie

Giant-Cell Arteritis Route of Administration

Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Giant-Cell Arteritis Molecule Type

Giant-Cell Arteritis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Giant-Cell Arteritis Pipeline Therapeutics Assessment

Giant-Cell Arteritis Assessment by Product Type
Giant-Cell Arteritis By Stage and Product Type
Giant-Cell Arteritis Assessment by Route of Administration
Giant-Cell Arteritis By Stage and Route of Administration
Giant-Cell Arteritis Assessment by Molecule Type
Giant-Cell Arteritis by Stage and Molecule Type

DelveInsight’s Giant-Cell Arteritis Report covers around 6+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Giant-Cell Arteritis product details are provided in the report. Download the Giant-Cell Arteritis pipeline report to learn more about the emerging Giant-Cell Arteritis therapies

Some of the key companies in the Giant-Cell Arteritis Therapeutics Market include:

Key companies developing therapies for Giant-Cell Arteritis are – Novartis, CSL, Kiniksa Pharmaceuticals, AbbVie, Johnson & Johnson, MorphoSys AG, and others.

Giant-Cell Arteritis Pipeline Analysis:

The Giant-Cell Arteritis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Giant-Cell Arteritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Giant-Cell Arteritis Treatment.
Giant-Cell Arteritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Giant-Cell Arteritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Giant-Cell Arteritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Giant-Cell Arteritis drugs and therapies

Giant-Cell Arteritis Pipeline Market Strengths

Improved and clear treatment and diagnostic guidelines has led the patients and practitioners to clearly diagnose and treat the patients accurately.
While glucocorticoids remain the primary treatment, there is ongoing research into alternative and adjunctive therapies, such as biologic agents like tocilizumab. This diversification in treatment options provides more tailored approaches for patients, considering factors like side effects and individual response.

Giant-Cell Arteritis Pipeline Market Opportunities

The development of targeted biologic therapies offers a significant opportunity for improving treatment outcomes in GCA. Biologics, such as interleukin-6 (IL-6) inhibitors like tocilizumab, have shown promise in clinical trials. Further research and development in this area can lead to more effective and targeted treatments.
The introduction of biosimilars for existing therapies can increase competition, potentially reducing treatment costs and improving accessibility for patients.

Scope of Giant-Cell Arteritis Pipeline Drug Insight

Coverage: Global
Key Giant-Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others
Key Giant-Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others
Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis current marketed and Giant-Cell Arteritis emerging therapies
Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers

Request for Sample PDF Report for Giant-Cell Arteritis Pipeline Assessment and clinical trials

Table of Contents

1. Giant-Cell Arteritis Report Introduction

2. Giant-Cell Arteritis Executive Summary

3. Giant-Cell Arteritis Overview

4. Giant-Cell Arteritis- Analytical Perspective In-depth Commercial Assessment

5. Giant-Cell Arteritis Pipeline Therapeutics

6. Giant-Cell Arteritis Late Stage Products (Phase II/III)

7. Giant-Cell Arteritis Mid Stage Products (Phase II)

8. Giant-Cell Arteritis Early Stage Products (Phase I)

9. Giant-Cell Arteritis Preclinical Stage Products

10. Giant-Cell Arteritis Therapeutics Assessment

11. Giant-Cell Arteritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Giant-Cell Arteritis Key Companies

14. Giant-Cell Arteritis Key Products

15. Giant-Cell Arteritis Unmet Needs

16 . Giant-Cell Arteritis Market Drivers and Barriers

17. Giant-Cell Arteritis Future Perspectives and Conclusion

18. Giant-Cell Arteritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys

Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Esophageal Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.
Esophageal Cancer companies working in the treatment market are CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment

Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.
In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA® (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.
In February 2024, Elevation Oncology, Inc. (Nasdaq: ELEV), a forward-thinking oncology company dedicated to developing targeted cancer therapies for patients with various solid tumors and significant unmet needs, has announced the expansion of its ongoing Phase 1 clinical trial of EO-3021 beyond the United States. The first patient has been dosed in Japan. The trial aims to assess the safety, tolerability, and initial anti-tumor effects of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors that are likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, and esophageal cancers.

Esophageal Cancer Overview

Esophageal cancer is a type of cancer that forms in the esophagus, the long tube that carries food from the throat to the stomach. It typically develops in two main types: squamous cell carcinoma, which occurs in the cells lining the esophagus, and adenocarcinoma, which starts in the mucus-secreting glands of the esophagus. Risk factors include smoking, heavy alcohol use, acid reflux (gastroesophageal reflux disease or GERD), obesity, and certain dietary habits. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Treatment options often include surgery, chemotherapy, and radiation, depending on the stage of the disease. Early detection is crucial for improving survival rates.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

CDR404: CDR-Life Inc.
M1231: Merck KGaA
Sotigalimab: Apexigen
Amivantamab: Genmab
Telomelysin: Oncolys BioPharma Inc
Tiragolumab: Genentech
S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.
CS1001: CStone Pharmaceuticals
Durvalumab: Celgene/MedImmune
Tucatinib: Seagen
APX 005M: Apexigen
Erdafitinib: Janssen Research & Development, LLC
Margetuximab: MacroGenics
AN-0025: Adlai Nortye

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Esophageal Cancer Molecule Type

Esophageal Cancer Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

Esophageal Cancer Assessment by Product Type
Esophageal Cancer By Stage and Product Type
Esophageal Cancer Assessment by Route of Administration
Esophageal Cancer By Stage and Route of Administration
Esophageal Cancer Assessment by Molecule Type
Esophageal Cancer by Stage and Molecule Type

DelveInsight’s Esophageal Cancer Report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Key companies developing therapies for Esophageal Cancer are – Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies

Esophageal Cancer Pipeline Market Drivers

Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers

However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight

Coverage: Global
Key Esophageal Cancer Companies: CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others
Key Esophageal Cancer Therapies: CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others
Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy

The 3D Urology and Prostate Clinics Announced Breakthroughs in 3D Targeted Prostate Treatment

The 3D Urology and Prostate Clinics are pioneering a revolutionary approach to prostate care with its advanced 3D Targeted Therapy.

The 3D Urology and Prostate Clinics, a leading institution in urological care, is proud to announce its significant advancements in prostate treatment through the implementation of 3D Targeted Therapy. This innovative approach provides patients with a more precise and effective alternative to traditional treatments. The clinic’s commitment to utilizing cutting-edge technology and personalized care is transforming the landscape of prostate health, offering new hope to patients worldwide.

The clinic’s proprietary 3D prostate Targeted Treatment is designed to address the specific needs of each patient, ensuring more accurate diagnosis and treatment. Unlike conventional methods that can sometimes be broad and indiscriminate, 3D Targeted Therapy focuses directly on affected areas of the prostate, minimizing harm to surrounding tissues. This method involves detailed imaging and mapping of the prostate, allowing doctors to visualize the exact location and extent of the condition. By using advanced medical imaging and diagnostic tools, the clinic can tailor each treatment plan to the individual patient’s unique circumstances, improving treatment outcomes. This precision reduces side effects and enhances the overall effectiveness of the treatment, leading to faster recovery and better long-term health.

At the core of the 3D Urology and Prostate Clinics’ approach is 3D Targeted Therapy, which is proving to be a game-changer for patients dealing with various prostate issues. This method provides a highly personalized approach, focusing on delivering treatment specifically to diseased areas while avoiding harm to healthy tissue. The clinic’s team of specialists employs sophisticated imaging techniques and diagnostic tools to create a detailed three-dimensional map of the prostate. This meticulous approach enhances the precision of treatments, reducing the risk of complications and improving overall efficacy. Patients who have undergone 3D Targeted Therapy have reported positive outcomes, highlighting the potential of this innovative treatment method.

The clinic’s dedication to improving patient outcomes is evident in the numerous positive patient testimonials. These stories highlight the effectiveness of 3D Targeted Therapy, demonstrating how it has transformed the lives of those suffering from various prostate conditions. Patients frequently praise the clinic for its personalized care and the effectiveness of the treatments. Their stories serve as powerful examples of how advanced techniques and personalized treatment plans can make a significant impact on patient health. The positive testimonials also serve as an encouragement for others seeking relief from prostate-related issues.

By combining advanced technology, personalized care, and a relentless pursuit of excellence, The 3D Urology and Prostate Clinics are setting a new standard in prostate treatment. The clinic remains committed to continuing its research and development, striving to further refine and enhance its 3D Targeted Therapy and ultimately improve the lives of patients worldwide. With a patient-focused approach, the clinic is leading the way in prostate treatment, offering hope and advanced care to those who need it most.

About The 3D Urology and Prostate Clinics

The 3D Urology and Prostate Clinics specialize in advanced prostate treatments, offering innovative 3D Targeted Therapy to improve patient outcomes through personalized and precise care.

Media Contact
Company Name: The 3D Urology and Prostate Clinics
Contact Person: Miss Alisa Wang
Email: Send Email
Phone: +86-18673216429 (WhatsApp)
State: Hunan Province
Country: China
Website: http://www.3dprostatecure.com

Angel Caregivers Continues Giving Access to 24/7 Live-In Caregivers in Chicago

Families in Chicago can now access reliable, 24-hour home care for their loved ones.

Chicago, IL – Angel Caregivers is pleased to announce the continuation of its 24/7 live-in caregiver services in Chicago, ensuring families have round-the-clock access to compassionate, professional in-home care for their loved ones. This initiative addresses a growing demand for 24-hour home care in Chicago, providing families with peace of mind that their loved ones receive high-quality, consistent care.

“At Angel Caregivers, our mission is to provide exceptional, reliable home care services that truly support families in Chicago,” said Vince Icao, representative of Angel Caregivers. “We understand the importance of offering continuity in caregiving, especially when it comes to the well-being and security of our clients. Our live-in caregivers are trained and committed to providing a compassionate presence, day and night, to ensure families can confidently support their loved ones.”

This service allowance comes as part of Angel Caregivers’ commitment to meet the needs of families in Chicago seeking reliable caregiving solutions, particularly those requiring continuous support for elderly or disabled loved ones. With trained caregivers available 24/7, clients benefit from personalized care plans, allowing them to remain safely in their homes and maintain a high quality of life. The live-in caregiver service includes assistance with daily activities, medical reminders, companionship, and customized support based on each client’s unique needs.

Twenty-four-hour care is increasingly essential for individuals with chronic conditions or cognitive impairments, where timely assistance can significantly improve daily comfort and health outcomes. Unlike traditional care schedules, live-in caregivers offer ongoing, uninterrupted support, reducing the risk of accidents or complications from delayed care. For families navigating the complexities of dementia, physical disabilities, or recovery from hospitalization, a 24/7 caregiver provides a safety net that fosters both stability and comfort at home.

Opting for 24-hour home care also allows family members to focus on quality time with their loved ones without the stress of meeting caregiving demands alone. With a skilled live-in caregiver, families can enjoy greater peace of mind knowing that a dedicated professional handles daily activities, provides companionship, and assists with medical reminders. This service enhances the family’s quality of life by balancing care responsibilities with personal time, enabling more positive and meaningful interactions with loved ones.

Choosing Angel Caregivers’ 24-hour home care offers families the advantage of a trusted, reputable agency committed to exceptional standards. Angel Caregivers meticulously selects and trains caregivers to ensure professionalism, reliability, and compassion. Each caregiver is matched to the client’s unique needs, creating a supportive environment that encourages independence and respects each individual’s dignity. Families looking for dependable 24/7 live-in caregiver Chicago services can trust Angel Caregivers for outstanding, tailored care solutions.

For families in Chicago looking for 24-hour home care, Angel Caregivers offers a dependable solution that prioritizes both client independence and family peace of mind. For more information on Angel Caregivers’ 24/7 live-in caregiver in Chicago, please visit their website at https://angelcaregiversinc.com.

About Angel Caregivers:

Angel Caregivers is a premier provider of in-home care services in Chicago, IL. Dedicated to enhancing the lives of seniors and individuals in need of assistance, Angel Caregivers offers a comprehensive range of home care services tailored to meet each client’s unique needs. With a commitment to compassionate, reliable care, Angel Caregivers has become a trusted choice for families across Chicago seeking high-quality, 24-hour home care solutions.

Media Contact
Company Name: Angel Caregivers Inc
Contact Person: Vince Icao
Email: Send Email
Phone: +1 708 585 0525
Address:306 Busse Hwy
City: Park Ridge
State: IL
Country: United States
Website: http://www.angelcaregiversinc.com

Astir Home Health Care Enhances Seniors’ Lives Through Dementia Home Care in Bloomfield, NJ

Leading provider of dementia and Alzheimer’s care reaffirms its commitment to personalized home care for seniors in Bloomfield, NJ.

Bloomfield, NJ – Astir Home Health Care continues its unwavering dedication to providing exceptional dementia home care in Bloomfield, NJ. This commitment ensures that seniors suffering from Alzheimer’s and dementia receive specialized, compassionate, and personalized care in the comfort of their homes. Astir Home Health Care prioritizes innovative and effective home care solutions to enhance seniors’ quality of life and ease the burden on their families as dementia-related illnesses rise.

“At Astir Home Health Care, we are deeply committed to enhancing the well-being of seniors through exceptional Alzheimer’s and dementia home care services,” said Cynthia Palmer, owner of Astir Home Health Care. “Our approach focuses on creating personalized care plans that cater to the unique needs of each individual. We believe that seniors deserve to live with dignity and comfort, and we proudly serve the Bloomfield, NJ community with dedication and compassion.”

The importance of Alzheimer’s and dementia home care in Bloomfield, NJ, cannot be overstated. Astir Home Health Care offers tailored services designed to improve safety, comfort, and mental well-being as families face the challenges of caring for loved ones with cognitive impairments. Their team of highly trained caregivers assists with daily living activities, memory care exercises, and emotional support, fostering a nurturing environment at home.

Dementia home care is essential for families because it allows seniors to remain in a familiar and comfortable environment, reducing confusion and anxiety often triggered by new or unfamiliar settings. Being in their own homes helps preserve a sense of normalcy, which is critical for individuals coping with memory loss. Personalized home care services provide structure and consistency, greatly enhancing a senior’s emotional and psychological well-being.

Additionally, professional dementia care services ensure that safety remains a top priority. Seniors with dementia are at higher risk for falls, wandering, and accidents. Trained caregivers are equipped to handle these risks and provide continuous monitoring to prevent injuries. They also implement strategies to make the home environment safer, allowing families to have peace of mind knowing their loved ones are protected.

Families considering dementia home care can also benefit from professional caregivers’ emotional support and respite. Caring for a loved one with dementia can be physically and emotionally exhausting. Families can avoid burnout and maintain their well-being by relying on skilled caregivers. This support allows family members to spend quality time with their loved ones without the constant strain of caregiving duties.

Families seeking trusted dementia care services can rely on Astir Home Health Care for comprehensive support. For more information about their dementia home care in Bloomfield, NJ, please visit their website at https://astirhc.com.

About Astir Home Health Care:

Astir Home Health Care is a leading provider of personalized home care services in Bloomfield, NJ, specializing in Alzheimer’s and dementia care. With a dedicated team of skilled caregivers, Astir Home Health Care aims to enhance the quality of life for seniors by offering compassionate, reliable, and individualized care plans. Their mission is to ensure seniors remain in their homes safely, comfortably, and with dignity.

Media Contact
Company Name: Astir Home Health Care
Contact Person: Cynthia Palmer
Email: Send Email
Phone: +1 973 259 1000
Address:192 Broad St
City: Bloomfield
State: NJ
Country: United States
Website: https://astirhc.com/

#1 Indy Home Care continue to provide access to Quality In-Home Care for Indiana Families

Families in Indianapolis now have easier access to compassionate in-home care with a network of skilled caregivers.

Indianapolis, IN – In a continued commitment to support Indianapolis families, Enchanted Hearts proudly announces the expansion of its in-home care services in Indiana, offering families a trustworthy solution to meet their caregiving needs. With a team of qualified caregivers in Indianapolis, IN, Enchanted Hearts ensures families have reliable support to care for their loved ones at home.

“Our mission at Enchanted Hearts has always been to bring peace of mind to families in Indiana by providing high-quality, compassionate care right where it matters most—at home,” said Shawndra Quinn, founder of Enchanted Hearts. “We are dedicated to connecting families with caregivers who are experienced and deeply committed to enriching the lives of those they serve.”

The growing need for in-home care services in Indiana reflects a shift towards providing seniors and those with chronic conditions the support they need to live safely and comfortably at home. Enchanted Hearts stands out by offering personalized care plans that adapt to the needs of each family, supporting seniors and individuals with health challenges. This initiative helps families avoid the high cost and disruption associated with institutional care, keeping loved ones in a familiar environment with skilled caregivers by their side.

Having qualified caregivers is invaluable for families, as they bring both professionalism and compassion to their roles. A trained caregiver can assist with daily activities such as bathing, meal preparation, and mobility support, which can be challenging for family members to manage alone. With this support, loved ones are safer and can maintain a greater sense of independence and dignity, which is essential for mental and emotional well-being.

Additionally, professional caregivers are trained to recognize and respond to health changes in clients, providing peace of mind to families who may worry about their loved one’s medical needs. They can assist with medication management, monitor vital signs, and help prevent health complications before they escalate. This level of attentiveness ensures that families in Indianapolis have a reliable resource in Enchanted Hearts’ caregivers, who are always looking out for the well-being of their clients.

Finally, having access to in-home caregivers also allows families to focus on their own well-being, balancing their personal and professional responsibilities while knowing their loved ones are in capable hands. For families who are often managing work, children, and other obligations, Enchanted Hearts provides the critical support needed to help them regain balance while their loved ones receive compassionate, dedicated care.

Families in Indianapolis looking for dependable in-home care in Indiana can rely on Enchanted Hearts for various services, from daily living assistance to comprehensive health support. To learn more about how Enchanted Hearts’ caregivers in Indianapolis can help, please visit their website at https://enchantedheartsllc.com.

About Enchanted Hearts Home Care:

Founded by Shawndra Quinn, Enchanted Hearts is a leading in-home care provider in Indiana, dedicated to offering compassionate, high-quality care. Known for their commitment to excellence, Enchanted Hearts connects families with professional caregivers who bring expertise and kindness to every interaction. Enchanted Hearts continues to make a positive difference in the lives of families across Indianapolis by ensuring that individuals receive the support they need to thrive at home.

Media Contact
Company Name: Enchanted Hearts Home Care
Contact Person: Shawndra Quinn
Email: Send Email
Phone: +14638887237
Address:650 N Girls School Rd
City: Indianapolis
State: IN
Country: United States
Website: enchantedheartsllc.com/

Sky Branding University Launches “Nonprofit Leadership Excellence & Brand Mastery for Fundraising Impact” Masterclass

Dr. Skye Saleh Releases New eBook on Leadership Excellence & Branding Strategies for Executives and Entrepreneurs

Seattle, WA – Sky Branding University, a for-profit small business, proudly announces the launch of its exclusive virtual masterclass, “Nonprofit Leadership Excellence & Brand Mastery for Fundraising Impact.” This masterclass is designed to help nonprofit leaders refine organizational strategies, enhance branding efforts, and strengthen stakeholder engagement. Scheduled for Tuesday, February 18, 2025, from 4:00 PM to 6:00 PM (PST), the event will be delivered virtually, making it accessible to nonprofit leaders nationwide.

Dr. Skye Saleh, Chief Leadership & Branding Officer and President of Sky Branding University, will facilitate the masterclass. With extensive leadership experience in various roles, including her former position as a C-suite executive in the nonprofit sector, Dr. Saleh has collaborated with leaders to improve organizational strategies and elevate brand presence. She holds a PhD and is committed to lifelong learning, having earned certifications in Leadership and Communication from Harvard University and Stanford University. Her dedication to advancing expertise in leadership and organizational strategies reflects her passion for excellence.

“Sky Branding University is committed to empowering nonprofit leaders by equipping them with the tools and strategies necessary to strengthen leadership practices and improve community impact. This masterclass will offer actionable insights on aligning organizational goals with strong branding to build deeper connections with stakeholders and drive success,” said Dr. Saleh.

In addition to the masterclass, Dr. Skye Saleh has released her new eBook, Leadership Excellence & Branding Strategies for Executives and Entrepreneurs to Build Influence and Achieve Sustainable Growth. The eBook includes a 30-Day Action Guide to Leadership Excellence & Branding, serving as a valuable resource for leaders looking to enhance their influence and create sustainable organizational growth strategies.

The Nonprofit Leadership Excellence & Brand Mastery for Fundraising Impact masterclass is tailored for nonprofit leaders, aspiring founders, and key stakeholders seeking to improve their leadership and branding skills. Participants will gain practical tools and strategies to implement immediately, helping them strengthen stakeholder engagement and improve fundraising efforts.

Event Details:

Date: Tuesday, February 18, 2025
Time: 4:00 PM – 6:00 PM (PST)
Location: Virtual Event
Registration Link: www.skybrandinguniversity.com
Cost: $75 per attendee

For more information, press inquiries, or media interviews, please contact:

Email: drskye@skybrandinguniversity.com
Phone: 1-800-458-0922
Website: www.skybrandinguniversity.com

Media Contact
Company Name: Sky Branding University
Contact Person: Dr. Skye Saleh
Email: Send Email
Country: United States
Website: https://www.skybrandinguniversity.com/

The Future of Digital Marketing is Here – Transform Any Business Size with an All-In-One AI-Powered Solution for 2025

Arryn.ai, a multi-award-winning digital marketing agency, is proud to announce the launch of its cutting-edge, AI-powered digital marketing services designed to revolutionize how businesses manage their online presence. With a full range of services, including web design, SEO, social media marketing, AI tools, and more, Arryn.ai is offering businesses the ultimate solution to streamline their marketing efforts and drive results—all for one price.

Key Features and Benefits of Arryn.ai’s New Product Launch:

● AI Digital Marketing Agency: Get a comprehensive digital marketing solution with powerful AI tools that automate and optimize campaigns for maximum effectiveness.

● Custom CEO Dashboard: Experience full transparency with a tailored CEO dashboard that offers real-time insights into performance, ROI, and key metrics.

● AI Chatbot & Brand Ambassador: Enhance customer engagement with a smart AI chatbot and brand ambassador that provides 24/7 interaction, delivering consistent brand messaging.

● Web Design & Development: Let Arryn.ai create stunning, high-performance websites tailored to any business brand and optimized for user experience.

● Social Media Management & Marketing: Boost business social presence with intelligent AI-driven content creation, engagement, and strategy across all platforms.

● Search Engine Optimization (SEO): Drive organic growth with AI-powered SEO tools that ensure the business website ranks higher and attracts more qualified traffic.

● AI Premium Tools: Access top-tier AI marketing and data analytics tools that give you a competitive edge.

● Domain & Web Hosting: Arryn.ai offers reliable, secure web hosting and domain management services to ensure each business website performs at its best.

● Data Analytics & Research: Unlock the power of data-driven insights to inform owners the best decision, strategy and drive business growth.

Why Arryn.ai?

Arryn.ai stands out in a crowded marketplace with over 3,000+ successful website projects completed and a proven track record of delivering fast, affordable, and effective digital marketing solutions. As a multi-award-winning agency, Arryn.ai offers unmatched expertise and a commitment to helping businesses of all sizes grow and succeed online.

With a focus on using AI to streamline operations and enhance the customer experience, Arryn.ai empowers businesses to achieve measurable ROI faster and more cost-effectively than ever before.

Exclusive 2025 Offer: 50% Off for a Limited Time

To celebrate the new year and help businesses get a head start on 2025, Arryn.ai is offering an exclusive 50% discount on all of its digital marketing AI services. No need to pay the whole team of web designer, developer, seo specialist, digital marketer, video editor, content writer, data analyst and project manager to manage any online business for more than $20,000 + a month.

Save up to 90% of any business overall overhead and marketing expenses with Arryn.ai for a price one, as low as $299/month, we got it covered for you. Plus, the use of custom CEO dashboard, AI chatbot, AI tools and AI Brand Ambassador.

This special offer makes it easier than ever to access a comprehensive AI-driven marketing solution for as little as $15,999 annually—a fraction of the cost it would take to hire multiple employees or agencies for the same services. It’s just like the normal expenses for just one month of operation or even more.

This limited-time offer is designed to help businesses optimize their marketing strategies and position themselves for success in the new year. The offer is available for a limited time, and it’s the perfect way to set business owners up for success this 2025.

What’s Included in the 2025 Digital Marketing AI Package Deal:

● Full AI digital marketing managed agency services (web design, SEO, social media, etc.)

● Custom CEO dashboard

● AI chatbot and brand ambassador

● Premium AI tools for marketing and data analytics

● Domain and web hosting

● Data-driven research and insights

This complete package provides everything businesses need to drive online growth and return on investment—all with the ease and efficiency of a single agency.

Don’t Miss Out on the Future of Digital Marketing!

Arryn.ai is offering businesses an unparalleled opportunity to streamline their digital marketing efforts, save time, and boost ROI with the power of AI. Whether you’re based in the United States or abroad, Arryn.ai is ready to help any type of business grow to the next level.

Start 2025 with the ultimate digital marketing solution. Visit this special link www.arryn.ai/2025-deal to take advantage of this limited-time offer today.

PS: Interested to earn extra? Earn up to $1,599 per successful referral. Join our affiliate program now at this link https://arryn.ai/join-arryn-ai-affiliate-program/. Interested to start an AI digital marketing agency as low as $299/month? Contact us to get started.

Media Contact
Company Name: Arryn.ai
Contact Person: Dr. Chris Dayagdag
Email: Send Email
City: Carson City
State: Nevada
Country: United States
Website: www.arryn.ai

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Future of Digital Marketing is Here – Transform Any Business Size with an All-In-One AI-Powered Solution for 2025